Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Depletion: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| UNC13A | associated_with | gene | 0.88 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Microglial Aging and Immune Memory in Neurodegeneration — Training the | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,960,000 |
| Normal Aging to Alzheimer's Disease Transition Trigger — Identifying t | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Peroxisomal Dysfunction Validation in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sirtuin Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Sirtuin Pathway Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and De [PMID:38580317] | Velma GR, Krider IS, Alves ETM, Courey J | J Med Chem | 2024 | 1 |
| NAD(+) metabolism, stemness, the immune response, and cancer. [PMID:33384409] | Navas LE, Carnero A | Signal Transduct Target Ther | 2021 | 1 |
| NAD metabolism fuels human and mouse intestinal inflammation. [PMID:28877980] | Gerner RR, Klepsch V, Macheiner S, Arnha | Gut | 2018 | 1 |
| NAD+ and sirtuins in aging and disease. [PMID:24786309] | Imai S, Guarente L | Trends Cell Biol | 2014 | 1 |
| Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affi [PMID:39676006] | ["Waldschmidt J", "Rasche L", "Kort\u00f | Clinical lymphoma, myeloma & l | 2025 | 0 |
| Protein Acetylation and NAD+ Homeostasis in Aging Muscle. [PMID:40879949] | Ji LL | Advances in experimental medic | 2025 | 0 |
| CD38 is a key mediator of NAD+ depletion in the brain of ZIKV-infected mice. [PMID:41362627] | Saraiva GN, Sousa BG, Souza NMS, Vitorin | iScience | 2025 | 0 |
| REV-ERBα regulates brain NAD+ levels and tauopathy via an NFIL3-CD38 axis. [PMID:40890338] | Lee J, Kang R, Park S, Saliu IO, Son M, | Nature aging | 2025 | 0 |
| Structure-based cheminformatics and molecular dynamics profiling of potential SI [PMID:40650732] | Al-Samydai A, Al-Mamoori F, Mayyas A, Or | Molecular diversity | 2025 | 0 |
| Dysregulation of Niacin-Derived NAD+ Salvage Pathway Markers (CD38, NAMPT, SIRT1 [PMID:41470091] | Huwaimel B, Alqarni S, Abouzied AS, Algh | Medicina (Kaunas, Lithuania) | 2025 | 0 |
| Computational Prediction of Amino Acid Preferences of Potentially Multispecific [PMID:38345234] | ["Cruz H", "Llanes A", "Fern\u00e1ndez P | Journal of visualized experime | 2024 | 0 |
| The frequency of CD38 [PMID:39358361] | ["Pisu D", "Johnston L", "Mattila J", "R | Nature communications | 2024 | 0 |
| Differential Diagnosis of Changes in Intraocular Lenses. [PMID:37567234] | ["Yildirim T", "Auffarth G", "Henningsen | Klinische Monatsblatter fur Au | 2023 | 0 |
| Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphor [PMID:38012567] | ["H\u00e4selbarth L", "Gamali S", "Saul | BMC cancer | 2023 | 0 |
| Real-Time Interfacial Nanothermometry Using DNA-PAINT Microscopy. [PMID:35789234] | ["Nooteboom S", "Wang Y", "Dey S", "Zijl | Small (Weinheim an der Bergstr | 2022 | 0 |
| Theoretical Study of Vinyl-Sulfonate Monomers and Their Effect as the Dopants of [PMID:36234890] | ["Rodr\u00edguez-S\u00e1nchez I", "Conej | Molecules (Basel, Switzerland) | 2022 | 0 |
| Teclistamab in Relapsed or Refractory Multiple Myeloma. [PMID:35661166] | ["Moreau P", "Garfall A", "van de Donk N | The New England journal of med | 2022 | 0 |
| Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from tw [PMID:33914175] | ["Driouk L", "Schmitt R", "Peters A", "H | Molecular and cellular pediatr | 2021 | 0 |
| Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised [PMID:33567890] | ["Wienholtz N", "Christensen C", "Zhang | Cephalalgia : an international | 2021 | 0 |
| Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. [PMID:33626253] | ["Munshi N", "Anderson L", "Shah N", "Ma | The New England journal of med | 2021 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Depletion in their description or question text
Score: 0.620 · neurodegeneration · 2026-04-22
## Mechanistic Overview Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD starts from the claim
Score: 0.501 · immunomics · 2026-04-25
CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege
Score: 0.475 · unknown disease · 2026-04-26
Retained intronic sequences contain cryptic nuclear retention elements that recruit export inhibitory complexes (PHAX, A
Score: 0.455 · molecular-biology · 2026-04-27
Nanobodies designed to preferentially penetrate cholesterol-depleted membranes could selectively target tau-containing v
Score: 0.455 · molecular-biology · 2026-04-27
Nanobodies engineered to selectively penetrate membranes in ATP-depleted environments could target tau-containing vesicl
Score: 0.380 · metabolomics · 2026-04-26
This hypothesis proposes that targeting CD38, the primary NAD+-consuming enzyme, represents a more direct therapeutic ap
Score: 0.000 · unknown disease · 2026-04-28
Designer antisense oligonucleotides targeting conserved secondary structures in dilncRNAs could selectively degrade thes
Score: 0.000 · unknown disease · 2026-04-28
Reduced Prevotellaceae abundance leads to decreased SCFA production, triggering neuroinflammation that accelerates PD pa
Score: 0.000 · unknown disease · 2026-04-28
Prevotellaceae loss leads to autoimmune targeting of dopaminergic neurons through molecular mimicry and regulatory T-cel